Chinese biopharmaceutical company: TQF3250 clinical trial application approved by NMPA and FDA.

Announcement from Chinese Biopharmaceuticals: The clinical trial application for TQF3250 capsules, an innovative drug developed independently by the group, a "GLP-1 receptor agonist for oral administration", has received approval from the China National Medical Products Administration and the U.S. Food and Drug Administration, intended for weight reduction.